Phase III Study: Rituxan Improved PFS By 79% In Advanced Follicular Lymphoma
ASCO Calls On NCI To Double Funding For Cooperative Group Clinical Trials
Tasigna Shows Benefit Over Gleevec In Phase III Study for Ph+ CML In Chronic Phase
Bosutinib Vs. Imatinib Study Didn’t Meet Primary Endpoint
Autologous BMT Equivalent To Allogeneic For Myeloma
Non-Adherence To Protocol Explains Outcome Differences In Hispanic Children With ALL
Afinitor Delayed Progression Compared To Tamoxifen Alone In Randomized Phase II Study
AZURE Trial: Zoledronic Acid Didn’t Improve DFS In Stage II/III
Survival For ALL Increased To 94 Percent In Recent Years
TTF Increased Survival Compared To Chemotherapy
Randomized Trial Finds Sunscreen Use Cuts Risk Of Developing Melanoma
Clinical Trials Approved By NCI CTEP Last Month
Trending Stories
- FY25 paylines drop to 4th percentile—a historic low—as NCI braces for Trump’s FY26 budget cuts
- In the Headlines: Is oncology ready to move away from animal testing?
- Right-wing provocateur Laura Loomer comes for FDA’s Vinay Prasad
- Imaging’s ride to the bottom in clinical trials—and why it matters now
- Oncologist biotech entrepreneur George Tidmarsh joins FDA as CDER director
His appointment came out of “proximity” to Makary and Bhattacharya - Will MCD tests revolutionize cancer screening? NCI begins enrollment in Vanguard “feasibility” trial to start finding out
